Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 390 participants.

Also called NCT07286747

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 390 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07286747
  • EU CT 2024-519903-88-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07286747. Randomized; triple masking; primary purpose prevention. Start 2026-03-03 (actual); primary completion 2028-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)
Acronym
CONCEPT
Condition
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Intervention (Drug)
controlled-ileal-release nicotinic acid as multiple dose 100 mg/day
Intervention (Drug)
controlled-ileal-release nicotinic acid as multiple dose 200 mg/day
Intervention (Drug)
controlled-ileal-release nicotinic acid as multiple dose placebo
Lead sponsor
University Hospital Schleswig-Holstein (class: other)

Record details

Record id
cardio:ct-nct07286747
Content hash
a32e0b7656427432952eec63b07e8eb5b5b7e596037ba265176a7b828ba609ae